Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Gains from Investment Securities: 2023-2025

  • Monte Rosa Therapeutics' Gains from Investment Securities fell 99.50% to $59,000 in Q1 2025 from the same period last year, while for Mar 2024 it was $11.7 million, marking a year-over-year increase of 15.99%. This contributed to the annual value of $11.6 million for FY2024, which is 23.36% up from last year.
  • According to the latest figures from Q1 2025, Monte Rosa Therapeutics' Gains from Investment Securities is $59,000, which was down 99.50% from $11.7 million recorded in Q1 2024.
  • In the past 5 years, Monte Rosa Therapeutics' Gains from Investment Securities registered a high of $11.7 million during Q1 2024, and its lowest value of $59,000 during Q1 2025.
  • In the last 3 years, Monte Rosa Therapeutics' Gains from Investment Securities had a median value of $5.1 million in 2023 and averaged $5.5 million.
  • In the last 5 years, Monte Rosa Therapeutics' Gains from Investment Securities climbed by 15.99% in 2024 and then slumped by 99.50% in 2025.
  • Monte Rosa Therapeutics' Gains from Investment Securities (Quarterly) stood at $155,000 in 2023, then rose by 15.99% to $11.7 million in 2024, then plummeted by 99.50% to $59,000 in 2025.
  • Its last three reported values are $59,000 in Q1 2025, $11.7 million for Q1 2024, and $155,000 during Q2 2023.